Stiolto Respimat (tiotropium bromide and olodaterol) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD). Stiolto Respimat can cause side effects that range from mild to ...

Stiolto Respimat (tiotropium bromide/olodaterol) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). It comes with an inhaler for breathing the drug into your ...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved ...

Boehringer Ingelheim announced new data from a Phase 3b study of Stiolto Respimat (tiotropium, olodaterol) in which treatment with Stiolto Respimat led to significant improvements in SGRQ total score ...

Stiolto Respimat received approval from the Food and Drug Administration (FDA) in May 2015. The Respimat inhaler actively delivers a slow-moving mist that aids the patient independent of inspiratory ...

These data, which are from the OTEMTO® 1&2 clinical studies, show a clinically meaningful improvement in health-related quality of life, as measured by the St. George's Respiratory Questionnaire (SGRQ ...

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO™ RESPIMAT ® (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the ...

RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & ...

Stiolto Respimat (tiotropium bromide/olodaterol) is an inhaled medication for the treatment of chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. However, it is not indicated for ...

FDA recently accepted sNDA filing to review data from DYNAGITO trial for inclusion in Stiolto Respimat label A COPD exacerbation, or a flare-up, is a sudden worsening of symptoms, such as increased ...